By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Shah, Manish S.; DiFalco, Ray J., filed on November 7, 2014, was made available online on March 12, 2015, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a company or ins
Release date- 26032015- Leverkusen,- Bayer HealthCare received approval in Japan for Gadovist injection for use with magnetic resonance imaging. Gadovist is the first high concentration/high relaxivity gadolinium-based contrast agent to be approved in Japan and is indicated for contrast-enhancement MRI in cranial, spinal, the body and extremeties a
Biomedical Systems reported its affiliation with the Electronic Patient-Reported Outcome Consortium, a program run by the Critical Path Institute. "Clinical outcome assessments are becoming more important in clinical trials to determine whether a drug has demonstrated a treatment benefit," said Timothy Barrett, chief operating officer at Biomedica
Boston Therapeutics, Inc., a leading developer of compounds that enable people to manage their blood glucose using complex carbohydrate chemistry, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2014 and provided a corporate update. David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics, said
Tony Fiorino, MD, PhD, Chief Executive Officer of BrainStorm, stated, "We are extremely pleased with the progress we made in 2014, which was very productive from a clinical as well as operational perspective. ?In June 2014, we commenced a U.S. multi-center, randomized, double-blind placebo-controlled phase 2 study of NurOwn in ALS:? Enrollme
You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing at the end of this Annual Report on Form 10- K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10- K
We are a biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs with a strategic commercial focus on the greater China market. Our mission is to deliver pharmaceutical drugs to patients with unmet medical needs directly in China, and in the r
"Over the past year, we have executed against this goal by building out a new management team, securing a Nasdaq listing, attracting new institutional investors, obtaining FDA approval to initiate clinical trials in two different orphan indications and publishing multiple high profile manuscripts detailing the groundbreaking nature of our product..
In the study six patients received Y90, 10 patients were treated with PHP, 12 patients were treated with CE, one patient received Y90 after PHP and one patient received PHP following treatment with CE. MVA showed improved HPFS for PHP versus Y90 and for PHP versus CE, but not for CE versus Y90. There was a significant difference on MVA of OS for PH
Earlier this year, the Capillus272Pro? received FDA clearance for the promotion of hair regrowth in adult men and women with androgenic alopecia having Ludwig Savin classifications I-II or Norwood Hamilton classifications of IIa-V and Fitzpatrick Classification of Skin phototypes I-IV. "I am extremely excited that the U.S. Food and Drug Administ
CAMBRIDGE, Mass.& NORTH CHICAGO, Ill. Today Biogen and AbbVie announced that the European Medicines Agency has validated the companies Marketing Authorisation Application for ZINBRYTA? for the treatment of relapsing forms of multiple sclerosis in the European Union. We are committed to bringing to market medicines that may provide remar
A team of researchers, led by Professor Fengcai Zhu, from the Jiangsu provincial centre for disease prevention and control in China, tested the safety and immunogenicity of a novel Ebola vaccine, based on the 2014 Zaire Guinea Ebola strain, and delivered by a viruslike structure, Science Daily reported. The experimental vaccine was developed by Bei
Flamel Technologies today announced the results of a First-in-Man clinical study in healthy volunteers using its proprietary LiquiTime drug delivery platform applied to guaifenesin, a broadly used expectorant. The chosen formulation will be optimized and scaled up over the coming months and Flamel plans to perform a pivotal study in 2016. There
Management's Discussion and Analysis of Financial Condition and Results of Operations. The following discussion of our financial condition and results of operations should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2014 found in this report. In addition to historical information, t
Bayer HealthCare received approval in Japan for Gadovist injection for use with magnetic resonance imaging. Gadovist is the first high concentration/high relaxivity gadolinium-based contrast agent to be approved in Japan and is indicated for contrast-enhancement MRI in cranial, spinal, the body and extremeties at a dose of 0.1 mL/kg body weight.
-Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system diseases and disorders, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2014. Minerva today announced that it received regulatory
-STOCKHOLM, March 26, 2015 Moberg Pharma AB today announced that the European Patent Office has issued Patent no. 2 672 962, relating to its topical treatment MOB-015 for onychomycosis. The patent is expected to be in effect until 2032. In September 2014, Moberg Pharma reported positive results from a Phase II study of MOB-015 and in January 2015
NephroGenex, Inc., a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced positive results on preclinical studies that evaluate Pyridorin as a treatment for acute kidney injury. The data are being presented today at the National Kidney Foundation's 2015 Spring Clinical Meetings.
NephroGenex reported financial results and business highlights for the fourth quarter and year ended December 31, 2014. "NephroGenex achieved important milestones in 2014, including a successful initial public offering, the launch and advancement of our pivotal Phase 3 PIONEER program evaluating Pyridorin in diabetic nephropathy, a favorable TQT..
NephroGenex, Inc. reported financial results and business highlights for the fourth quarter and year ended December 31, 2014. "NephroGenex achieved important milestones in 2014, including a successful initial public offering, the launch and advancement of our pivotal Phase 3 PIONEER program evaluating Pyridorin in diabetic nephropathy, a favorable
Ohr Pharmaceutical, Inc., an ophthalmology research and development company, today announced the topline results from the exploratory Phase II IMPACT study evaluating OHR-102 combination therapy for the treatment of the wet form of age-related macular degeneration. In the intent-to-treat population with classic containing choroidal...
-Orion Corporation and the HUCH Comprehensive Cancer Center have entered into an extensive cooperation agreement. It will help us develop the treatment of cancer patients even further, "says Director Petri Bono from the HUCH Comprehensive Cancer Center. In our collaboration with the HUCH Comprehensive Cancer Center, I believe we will have the best
PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box , today announced that the genetically modified cells that are required for its three planned clinical trials have been fully tested and are in t
PierianDx also announced the addition of clinical trials, FDA drug labels, and treatment guidelines from the National Comprehensive Cancer Network and the American Society of Clinical Oncology to its knowledgebase. Inc. into the database are molecular matching to clinical trials, FDA drug labels, and treatment guidelines from NCCN and ASCO.